Therefore we utilised the transgenic Scl-tTa-BCR-ABL mouse model31 to investigate the effect of in vivo treatment with LDE225 ± nilotinib on CP-CML LSC (Fig. 7A,B). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.